Open AccessClinical trial of fusidic acid for lepromatous leprosy
Author(s) -
Scott G. Franzblau,
Gertrude P. Chan,
B G Garcia-Ignacio,
Venus Chavez,
J B Livelo,
Carmen Jiménez,
M L Parrilla,
R F Calvo,
Diana L. Williams,
Thomas P. Gillis
Publication year - 1994
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.38.7.1651
Subject(s) - fusidic acid , lepromatous leprosy , leprosy , medicine , antibiotics , gastroenterology , clinical trial , rifampicin , microbiology and biotechnology , dermatology , bacteria , biology , staphylococcus aureus , genetics
Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom